Fjarde Ap-fonden’s Royalty Pharma RPRX Stock Holding History

Fjarde Ap-fonden’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.99M	Buy	178,150 +9,900	+6%	+$515K	0.05%	306
2026 Q1	$8.07M	Buy	168,250 +49,900	+42%	+$2.19M	0.04%	328
2025 Q4	$4.57M	Sell	118,350 -4,000	-3%	-$153K	0.04%	357
2025 Q3	$4.32M	Buy	122,350 +3,700	+3%	+$134K	0.04%	346
2025 Q2	$4.28M	Buy	118,650 +31,100	+36%	+$1.03M	0.04%	356
2025 Q1	$2.73M	Sell	87,550 -39,000	-31%	-$1.24M	0.03%	407
2024 Q4	$3.23M	Buy	126,550 +41,300	+48%	+$1.1M	0.03%	417
2024 Q3	$2.41M	Buy	+85,250	New	+$2.36M	0.02%	454
2024 Q1	$2.87M	Sell	94,550 -19,300	-17%	-$569K	0.03%	459
2023 Q4	$3.2M	Buy	113,850 +32,000	+39%	+$879K	0.04%	436
2023 Q3	$2.22M	Sell	81,850 -7,100	-8%	-$211K	0.03%	471
2023 Q2	$2.73M	Sell	88,950 -43,600	-33%	-$1.48M	0.03%	446
2023 Q1	$4.78M	Buy	132,550 +29,350	+28%	+$1.09M	0.06%	323
2022 Q4	$4.08M	Sell	103,200 -6,100	-6%	-$255K	0.06%	341
2022 Q3	$4.59M	Hold	109,300	–	–	0.06%	349
2022 Q2	$4.59M	Sell	109,300 -32,600	-23%	-$1.34M	0.06%	349
2022 Q1	$5.53M	Buy	141,900 +21,400	+18%	+$840K	0.05%	366
2021 Q4	$4.8M	Buy	120,500 +57,600	+92%	+$2.24M	0.04%	408
2021 Q3	$2.27M	Buy	62,900 +700	+1%	+$27.2K	0.02%	533
2021 Q2	$2.55M	Sell	62,200 -4,500	-7%	-$191K	0.02%	532
2021 Q1	$2.91M	Buy	66,700 +24,300	+57%	+$1.15M	0.03%	516
2020 Q4	$2.12M	Buy	+42,400	New	+$1.8M	0.02%	540

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fjarde Ap-fonden's RPRX Position: Q2 2026 in Review

Fjarde Ap-fonden increased its Royalty Pharma (RPRX) stake by 5.9% in Q2 2026, buying an estimated $515K and bringing the position to 178,150 shares worth $9.99M. The position accounts for 0.05% of the portfolio, ranked #306.

Fjarde Ap-fonden first reported a position in RPRX in Q4 2020 and has held it in 22 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Fjarde Ap-fonden held 178,150 shares of Royalty Pharma worth $9.99M as of Q2 2026.
Fjarde Ap-fonden bought 9,900 Royalty Pharma shares in Q2 2026, an estimated $515K.
Royalty Pharma made up 0.05% of Fjarde Ap-fonden's portfolio in Q2 2026, its #306 holding.
Fjarde Ap-fonden first reported a position in Royalty Pharma in Q4 2020 and has held it in 22 quarters since.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Fjarde Ap-fonden's 13F filing for Q2 2026, filed 29 Jul 2026.